Advanced search
Publication Cover
Future Oncology Volume 6, 2010 - Issue 9
Submit an article Journal homepage
375
Views
0
CrossRef citations to date
0
Altmetric
Review

Why Target PIM1 for Cancer Diagnosis and Treatment?

Nancy S Magnuson1 School of Molecular Biosciences, Washington State University, Pullman, WA99164–7520, USA. [email protected]Correspondence[email protected]
View further author information
,
Zeping Wang1 School of Molecular Biosciences, Washington State University, Pullman, WA99164–7520, USA. [email protected]View further author information
,
Gang Ding2 Medical College, Shanghai Jiaotong University, Shanghai, ChinaView further author information
&
Raymond Reeves1 School of Molecular Biosciences, Washington State University, Pullman, WA99164–7520, USA. [email protected]View further author information
Pages 1461-1478 | Published online: 04 Oct 2010

Bibliography

  • Qian KC , WangL, HickeyERet al.: Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase.J. Biol. Chem.280, 6130–6137 (2005).
  • Cuypers HT , SeltenG, QuintWet al.: Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region.Cell37, 141–150 (1984).
  • Wingett D , ReevesR, MagnusonNS: Characterization of the testes-specific PIM-1 transcript in rat.Nucleic Acids Res.20, 3183–3189 (1992).
  • van Lohuizen M , VerbeekS, KrimpenfortPet al.: Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors.Cell56, 673–682 (1989).
  • Verbeek S , van LohuizenM, DomenJ, KraalG, BernsA: Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally.Mol. Cell Biol.11, 1176–1179 (1991).
  • Wang J , KimJ, RohMet al.: Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma.Oncogene29, 2477–2487(2010).
  • Dhanasekaran SM , BarretteTR, GhoshDet al.: Delineation of prognostic biomarkers in prostate cancer.Nature412, 822–826 (2001).
  • Valdman A , FangX, PangST, EkmanP, EgevadL: Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer.Prostate60, 367–371 (2004).
  • Ellwood-Yen K , GraeberTG, WongvipatJet al.: Myc-driven murine prostate cancer shares molecular features with human prostate tumors.Cancer Cell, 4, 223–238 (2003).
  • Roh M , SongC, KimJ, AbdulkadirSA: Chromosomal instability induced by Pim-1 is passage-dependent and associated with dysregulation of cyclin B1.J. Biol. Chem.280, 40568–40577 (2005).
  • Roh M , FrancoOE, HaywardSW, van der MeerR, AbdulkadirSA: A role for polyploidy in the tumorigenicity of Pim-1-expressing human prostate and mammary epithelial cells.PLoS One3, E2572 (2008).
  • Kim J , RohM, AbdulkadirSA: Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.BMC Cancer10, 248 (2010).
  • Zhang Y , WangZ, LiX, MagnusonNS: Pim kinase-dependent inhibition of c-Myc degradation.Oncogene27, 4809–4819 (2008).
  • Zippo A , De RobertisA, SerafiniR, OlivieroS: PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation.Nat. Cell Biol.9, 932–944 (2007).
  • Laird PW , van der LugtNM, ClarkeAet al.: In vivo analysis of Pim-1 deficiency.Nucleic Acids Res.21, 4750–4755 (1993).
  • van der Lugt NM , DomenJ, VerhoevenEet al.: Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2.EMBO J.14, 2536–2544 (1995).
  • Domen J , van der LugtNM, LairdPW, SarisCJ, BernsA: Analysis of Pim-1 function in mutant mice.Leukemia, 7(Suppl. 2), S108–S112 (1993).
  • Fox CJ , HammermanPS, CinalliRMet al.: The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor.Genes Dev., 17, 1841–1854 (2003).
  • Toker A : Signaling through protein kinase C.Front. Biosci.3, D1134–D1147 (1998).
  • Feliciello A , GottesmanME, AvvedimentoEV: The biological functions of A-kinase anchor proteins.J. Mol. Biol.308, 99–114 (2001).
  • Alessi DR , DeakM, CasamayorAet al.: 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase.Curr. Biol.7, 776–789 (1997).
  • Stokoe D , StephensLR, CopelandTet al.: Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B.Science277, 567–570 (1997).
  • Filippa N , SableCL, HemmingsBA, Van ObberghenE: Effect of phosphoinositide-dependent kinase 1 on protein kinase B translocation and its subsequent activation.Mol. Cell Biol.20, 5712–5721 (2000).
  • Bachmann M , MoroyT: The serine/threonine kinase Pim-1.Int. J. Biochem. Cell Biol.37, 726–730 (2005).
  • Domen J , van der LugtNM, ActonD, LairdPW, LindersK, BernsA: Pim-1 levels determine the size of early B lymphoid compartments in bone marrow.J. Exp. Med.178, 1665–1673 (1993).
  • Mochizuki T , KitanakaC, NoguchiK, MuramatsuT, AsaiA, KuchinoY: Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway.J. Biol. Chem.274, 18659–18666 (1999).
  • Wang Z , BhattacharyaN, MixterPF, WeiW, SedivyJ, MagnusonNS: Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase.Biochim. Biophys. Acta1593, 45–55 (2002).
  • Morishita D , KatayamaR, SekimizuK, TsuruoT, FujitaN: Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels.Cancer Res.68, 5076–5085 (2008).
  • Domen J , van der LugtNM, LairdPWet al.: Impaired interleukin-3 response in Pim-1-deficient bone marrow-derived mast cells.Blood82, 1445–1452 (1993).
  • Lilly M , KraftA: Enforced expression of the Mr 33,000 Pim-1 kinase enhances factor-independent survival and inhibits apoptosis in murine myeloid cells.Cancer Res.57, 5348–5355 (1997).
  • Lilly M , SandholmJ, CooperJJ, KoskinenPJ, KraftA: The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway.Oncogene18, 4022–4031 (1999).
  • Mikkers H , NawijnM, AllenJet al.: Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors.Mol. Cell Biol.24, 6104–6115 (2004).
  • Wang Z , BhattacharyaN, WeaverMet al.: Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis.J. Vet. Sci.2, 167–179 (2001).
  • Amaravadi R , ThompsonCB: The survival kinases Akt and Pim as potential pharmacological targets.J. Clin. Invest, 115, 2618–2624 (2005).
  • Moroy T , GrzeschiczekA, PetzoldS, HartmannKU: Expression of a Pim-1 transgene accelerates lymphoproliferation and inhibits apoptosis in lpr/lpr mice.Proc. Natl Acad. Sci. USA90, 10734–10738 (1993).
  • Rahman Z , YoshikawaH, NakajimaY, TasakaK: Down-regulation of Pim-1 and Bcl-2 is accompanied with apoptosis of interleukin-6-depleted mouse B-cell hybridoma 7TD1 cells.Immunol. Lett.75, 199–208 (2001).
  • Vaux DL , CoryS, AdamsJM: Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells.Nature335, 440–442 (1988).
  • Hockenbery D , NunezG, MillimanC, SchreiberRD, KorsmeyerSJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death.Nature348, 334–336 (1990).
  • Miyashita T , ReedJC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line.Blood81, 151–157 (1993).
  • Aho TL , SandholmJ, PeltolaKJ, MankonenHP, LillyM, KoskinenPJ: Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site.FEBS Lett.571, 43–49 (2004).
  • Zhou XM , LiuY, PayneG, LutzRJ, ChittendenT: Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155.J. Biol. Chem.275, 25046–25051 (2000).
  • Hirai I , WangHG: Survival-factor-induced phosphorylation of Bad results in its dissociation from Bcl-x(L) but not Bcl-2.Biochem. J.359, 345–352 (2001).
  • Chao DT , LinetteGP, BoiseLH, WhiteLS, ThompsonCB, KorsmeyerSJ: Bcl-XL and Bcl-2 repress a common pathway of cell death.J. Exp. Med.182, 821–828 (1995).
  • Yang E , ZhaJ, JockelJ, BoiseLH, ThompsonCB, KorsmeyerSJ: Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death.Cell80, 285–291 (1995).
  • Campbell PJ , GreenAR: The myeloproliferative disorders.N. Engl. J. Med.355, 2452–2466 (2006).
  • Delhommeau F , PisaniDF, JamesC, CasadevallN, ConstantinescuS, VainchenkerW: Oncogenic mechanisms in myeloproliferative disorders.Cell Mol. Life Sci., 63, 2939–2953 (2006).
  • Rane SG , ReddyEP: Janus kinases: components of multiple signaling pathways.Oncogene19, 5662–5679 (2000).
  • Kisseleva T , BhattacharyaS, BraunsteinJ, SchindlerCW: Signaling through the JAK/STAT pathway, recent advances and future challenges.Gene285, 1–24 (2002).
  • Didichenko SA , SpieglN, BrunnerT, DahindenCA: IL-3 induces a Pim1-dependent antiapoptotic pathway in primary human basophils.Blood112, 3949–3958 (2008).
  • Gozgit JM , BebernitzG, PatilPet al.: Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2.J. Biol. Chem.283, 32334–32343 (2008).
  • Mizuno K , ShiroganeT, ShinoharaA, IwamatsuA, HibiM, HiranoT: Regulation of Pim-1 by Hsp90.Biochem. Biophys. Res. Commun.281, 663–669 (2001).
  • Shay KP , WangZ, XingPX, McKenzieIF, MagnusonNS: Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway.Mol. Cancer Res.3, 170–181 (2005).
  • Andina N , DidichenkoS, Schmidt-MendeJ, DahindenCA, SimonHU: Proviral integration site for Moloney murine leukemia virus 1, but not phosphatidylinositol-3 kinase, is essential in the antiapoptotic signaling cascade initiated by IL-5 in eosinophils.J. Allergy Clin. Immunol.123, 603–611 (2009).
  • Sathyanarayana P , DevA, FangJet al.: EPO receptor circuits for primary erythroblast survival.Blood111, 5390–5399 (2008).
  • Yao Q , NishiuchiR, KitamuraT, KerseyJH: Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway.Leukemia19, 1605–1612 (2005).
  • Kim KT , BairdK, AhnJYet al.: Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival.Blood105, 1759–1767 (2005).
  • Xie Y , BurcuM, BaerMR: The serine/threonine kinase Pim-1 stabilizes 130 kilodalton FLT3 and promotes aberrant signaling through STAT5 in acute myeloid leukemia cells with FLT3 internal tandem duplication: synergistic apoptosis induction by Pim-1 and FLT3 inhibitors. Presented at:51st ASH Annual Meeting and Exposition. New Orleans, LA, USA, 5–8 December 2009.
  • Nieborowska-Skorska M , HoserG, KossevP, WasikMA, SkorskiT: Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis.Blood99, 4531–4539 (2002).
  • Klejman A , SchreinerSJ, Nieborowska‑SkorskaMet al.: The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.EMBO J.21, 5766–5774 (2002).
  • Chen JL , LimnanderA, RothmanPB: Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene.Blood111, 1677–1685 (2008).
  • Druker BJ , TamuraS, BuchdungerEet al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.Nat. Med.2, 561–566 (1996).
  • Xie Y , XuK, DaiBet al.: The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs.Oncogene, 25, 70–78 (1996).
  • Xie Y , XuK, LinnDEet al.: The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells.J. Biol. Chem.283, 3349–3356 (2008).
  • Fox CJ , HammermanPS, ThompsonCB: The Pim kinases control rapamycin-resistant T cell survival and activation.J. Exp. Med.201, 259–266 (2005).
  • Welsh SJ , KohMY, PowisG: The hypoxic inducible stress response as a target for cancer drug discovery.Semin. Oncol.33, 486–497 (2006).
  • Dairkee SH , NicolauM, SayeedAet al.: Oxidative stress pathways highlighted in tumor cell immortalization: association with breast cancer outcome.Oncogene26, 6269–6279 (2007).
  • Chen J , KobayashiM, DarmaninSet al.: Hypoxia-mediated up-regulation of Pim-1 contributes to solid tumor formation.Am. J. Pathol.175, 400–411 (2009).
  • Reiser-Erkan C , ErkanM, PanZet al.: Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma.Cancer Biol. Ther.7, 1352–1359 (2008).
  • Zemskova M , SahakianE, BashkirovaS, LillyM: The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells.J. Biol. Chem.283, 20635–20644 (2008).
  • Hammerman PS , FoxCJ, CinalliRMet al.: Lymphocyte transformation by Pim-2 is dependent on nuclear factor-κB activation.Cancer Res.64, 8341–8348 (2004).
  • Lin HL , LiuTY, ChauGY, LuiWY, ChiCW: Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species.Cancer89, 983–994 (2000).
  • Hinz M , LoserP, MathasS, KrappmannD, DorkenB, ScheidereitC: Constitutive NF-κB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells.Blood97, 2798–2807 (2001).
  • Chen Z , SeimiyaH, NaitoMet al.: ASK1 mediates apoptotic cell death induced by genotoxic stress.Oncogene18, 173–180 (1999).
  • Gu JJ , WangZ, ReevesR, MagnusonNS: PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis.Oncogene28, 4261–4271 (2009).
  • Burgering BM , KopsGJ: Cell cycle and death control: long live Forkheads.Trends Biochem. Sci.27, 352–360 (2002).
  • Plas DR , ThompsonCB: Akt activation promotes degradation of tuberin and FoxO3a via the proteasome.J. Biol. Chem.278, 12361–12366 (2003).
  • Yang JY , ZongCS, XiaWet al.: ERK promotes tumorigenesis by inhibiting FoxO3a via MDM2-mediated degradation.Nat. Cell Biol.10, 138–148 (2008).
  • Michael D , OrenM: The p53-Mdm2 module and the ubiquitin system.Semin. Cancer Biol.13, 49–58 (2003).
  • Hogan C , HutchisonC, MarcarLet al.: Elevated levels of oncogenic protein kinase Pim-1 induce the p53 pathway in cultured cells and correlate with increased Mdm2 in mantle cell lymphoma.J. Biol. Chem.283, 18012–18023 (2008).
  • Bueso-Ramos CE , ManshouriT, HaidarMA, HuhYO, KeatingMJ, AlbitarM: Multiple patterns of MDM-2 deregulation in human leukemias: implications in leukemogenesis and prognosis.Leuk. Lymphoma17, 13–18 (1995).
  • Finnegan MC , GoepelJR, RoydsJ, HancockBW, GoynsMH: Elevated levels of MDM-2 and p53 expression are associated with high grade non-Hodgkin’s lymphomas.Cancer Lett.86, 215–221 (1994).
  • Murray SA , YangS, DemiccoEet al.: Increased expression of MDM2, cyclin D1, and p27Kip1 in carcinogen-induced rat mammary tumors.J. Cell Biochem.95, 875–884 (2005).
  • Dworakowska D , JassemE, JassemJet al.: MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC).Lung Cancer43, 285–295 (2004).
  • Kondo I , IidaS, TakagiY, SugiharaK: MDM2 mRNA expression in the p53 pathway may predict the potential of invasion and liver metastasis in colorectal cancer.Dis. Colon Rectum51, 1395–1402 (2008).
  • Jeczen R , SkomraD, CybulskiMet al.: P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome.Clin. Exp. Metastasis24, 503–511 (2007).
  • Quesnel B , PreudhommeC, OscierDet al.: Over-expression of the MDM2 gene is found in some cases of haematological malignancies.Br. J. Haematol.88, 415–418 (1994).
  • Iwakuma T , LozanoG: MDM2, an introduction.Mol. Cancer Res.1, 993–1000 (2003).
  • Dautry F , WeilD, YuJ, Dautry-VarsatA: Regulation of pim and myb mRNA accumulation by interleukin 2 and interleukin 3 in murine hematopoietic cell lines.J. Biol. Chem.263, 17615–17620 (1988).
  • Wingett D , ReevesR, MagnusonNS: Stability changes in pim-1 proto-oncogene mRNA after mitogen stimulation of normal lymphocytes.J. Immunol.147, 3653–3659 (1991).
  • Buckley AR , BuckleyDJ, LeffMA, HooverDS, MagnusonNS: Rapid induction of pim-1 expression by prolactin and interleukin-2 in rat Nb2 lymphoma cells.Endocrinology136, 5252–5259 (1995).
  • Krishnan N , PanH, BuckleyDJ, BuckleyA: Prolactin-regulated pim-1 transcription: identification of critical promoter elements and Akt signaling.Endocrine20, 123–130 (2003).
  • Liang H , HittelmanW, NagarajanL: Ubiquitous expression and cell cycle regulation of the protein kinase PIM-1.Arch. Biochem. Biophys.330, 259–265 (1996).
  • Miura O , MiuraY, NakamuraNet al.: Induction of tyrosine phosphorylation of Vav and expression of Pim-1 correlates with Jak2-mediated growth signaling from the erythropoietin receptor.Blood84, 4135–4141 (1994).
  • Shirogane T , FukadaT, MullerJM, ShimaDT, HibiM, HiranoT: Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis.Immunity.11, 709–719 (1999).
  • Wingett D , LongA, KelleherD, MagnusonNS: pim-1 proto-oncogene expression in anti-CD3-mediated T cell activation is associated with protein kinase C activation and is independent of Raf-1.J. Immunol.156, 549–557 (1996).
  • Siegel JN , KlausnerRD, RappUR, SamelsonLE: T cell antigen receptor engagement stimulates c-raf phosphorylation and induces c-raf-associated kinase activity via a protein kinase C-dependent pathway.J. Biol. Chem.265, 18472–18480 (1990).
  • Altman A , IsakovN, BaierG: Protein kinase Cq: a new essential superstar on the T-cell stage.Immunol. Today21, 567–573 (2000).
  • Trushin SA , PenningtonKN, CarmonaEMet al.: Protein kinase Cα (PKCα) acts upstream of PKCθ to activate IκB kinase and NF-κB in T lymphocytes.Mol. Cell Biol.23, 7068–7081 (2003).
  • Zhu N , RamirezLM, LeeRL, MagnusonNS, BishopGA, GoldMR: CD40 signaling in B cells regulates the expression of the Pim-1 kinase via the NF-κ B pathway.J. Immunol.168, 744–754 (2002).
  • Bachmann M , HennemannH, XingPX, HoffmannI, MoroyT: The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle checkpoint.J. Biol. Chem.279, 48319–48328 (2004).
  • Bachmann M , KosanC, XingPX, MontenarhM, HoffmannI, MoroyT: The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C.Int. J. Biochem. Cell Biol.38, 430–443 (2006).
  • Zhang Y , WangZ, MagnusonNS: Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells.Mol. Cancer Res.5, 909–922 (2007).
  • Maga G , HubscherU: Proliferating cell nuclear antigen (PCNA): a dancer with many partners.J. Cell Sci.116, 3051–3060 (2003).
  • Prives C , GottifrediV: The p21 and PCNA partnership: a new twist for an old plot.Cell Cycle7, 3840–3846 (2008).
  • Bhattacharya N , WangZ, DavittC, McKenzieIF, XingPX, MagnusonNS: Pim-1 associates with protein complexes necessary for mitosis.Chromosoma111, 80–95 (2002).
  • Koike N , MaitaH, TairaT, ArigaH, Iguchi-ArigaSM: Identification of heterochromatin protein 1 (HP1) as a phosphorylation target by Pim-1 kinase and the effect of phosphorylation on the transcriptional repression function of HP1(1).FEBS Lett.467, 17–21 (2000).
  • Horsley D , HutchingsA, ButcherGW, SinghPB: M32, a murine homologue of Drosophila heterochromatin protein 1 (HP1), localises to euchromatin within interphase nuclei and is largely excluded from constitutive heterochromatin.Cytogenet. Cell Genet.73, 308–311 (1996).
  • Roh M , GaryB, SongCet al.: Overexpression of the oncogenic kinase Pim-1 leads to genomic instability.Cancer Res.63, 8079–8084 (2003).
  • Roh M , SongC, KimJ, AbdulkadirSA: Chromosomal instability induced by Pim-1 is passage-dependent and associated with dysregulation of cyclin B1.J. Biol. Chem.280, 40568–40577 (2005).
  • Roh M , FrancoOE, HaywardSW, van der MeerR, AbdulkadirSA: A role for polyploidy in the tumorigenicity of Pim-1-expressing human prostate and mammary epithelial cells.PLoS One3, E2572 (2008).
  • Jung YJ , ChaeHC, SeohJYet al.: Pim-1 induced polyploidy but did not affect megakaryocytic differentiation of K562 cells and CD34+ cells from cord blood.Eur. J. Haematol.78, 131–138 (2007).
  • Eichmann A , YuanL, BreantC, AlitaloK, KoskinenPJ: Developmental expression of pim kinases suggests functions also outside of the hematopoietic system.Oncogene19, 1215–1224 (2000).
  • Wang Z , ZhangY, GuJJ, DavittC, ReevesR, MagnusonNS: Pim-2 phosphorylation of p21(Cip1/WAF1) enhances its stability and inhibits cell proliferation in HCT116 cells.Int. J. Biochem. Cell Biol.42, 1030–1038 (2010).
  • Chen WW , ChanDC, DonaldC, LillyMB, KraftAS: Pim family kinases enhance tumor growth of prostate cancer cells.Mol. Cancer Res.3, 443–451 (2005).
  • Thompson J , PeltolaKJ, KoskinenPJ, JanneOA, PalvimoJJ: Attenuation of androgen receptor-dependent transcription by the serine/threonine kinase Pim-1.Lab. Invest.83, 1301–1309 (2003).
  • van der Poel HG , ZevenhovenJ, BergmanAM: Pim1 regulates androgen-dependent survival signaling in prostate cancer cells.Urol. Int.84, 212–220 (2010).
  • Hilton DJ , RichardsonRT, AlexanderWSet al.: Twenty proteins containing a C-terminal SOCS box form five structural classes.Proc. Natl Acad. Sci. USA95, 114–119 (1998).
  • Lilly M , LeT, HollandP, HendricksonSL: Sustained expression of the pim-1 kinase is specifically induced in myeloid cells by cytokines whose receptors are structurally related.Oncogene7, 727–732 (1992).
  • Mui AL , WakaoH, KinoshitaT, KitamuraT, MiyajimaA: Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: role of Stat5 in proliferation.EMBO J.15, 2425–2433 (1996).
  • Chen XP , LosmanJA, CowanSet al.: Pim serine/threonine kinases regulate the stability of Socs-1 protein.Proc. Natl Acad. Sci. USA99, 2175–2180 (2002).
  • Peltola KJ , PaukkuK, AhoTL, RuuskaM, SilvennoinenO, KoskinenPJ: Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3.Blood103, 3744–3750 (2004).
  • Shah N , PangB, YeohKGet al.: Potential roles for the PIM1 kinase in human cancer – a molecular and therapeutic appraisal.Eur. J. Cancer44, 2144–2151 (2008).
  • Brault L , GasserC, BracherF, HuberK, KnappS, SchwallerJ: PIM serine/threonine kinases in pathogenesis and therapy of hematological malignancies and solid cancers.Haematologica DOI: 10.3324/haematol.2009.017079 (2010) (Epub ahead of print).
  • Chen CN , LinJJ, ChenJJet al.: Gene expression profile predicts patient survival of gastric cancer after surgical resection.J. Clin. Oncol.23, 7286–7295 (2005).
  • Cibull TL , JonesTD, LiLet al.: Overexpression of Pim-1 during progression of prostatic adenocarcinoma.J. Clin. Pathol.59, 285–288 (2006).
  • Xu Y , ZhangT, TangHet al.: Overexpression of PIM-1 is a potential biomarker in prostate carcinoma.J. Surg. Oncol.92, 326–330 (2005).
  • He HC , BiXC, ZhengZWet al.: Real-time quantitative RT-PCR assessment of PIM-1 and hK2 mRNA expression in benign prostate hyperplasia and prostate cancer.Med. Oncol.26, 303–308 (2009).
  • Buchholz M , BraunM, HeidenblutAet al.: Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions.Oncogene24, 6626–6636 (2005).
  • Beier UH , WeiseJB, LaudienM, SauerweinH, GoroghT: Overexpression of Pim-1 in head and neck squamous cell carcinomas.Int. J. Oncol.30, 1381–1387 (2007).
  • Peltola K , HollmenM, MaulaSMet al.: Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor.Neoplasia11, 629–636 (2009).
  • Choi JY , ChoSI, DoNY, KangCY, LimSC: Clinical significance of the expression of galectin-3 and Pim-1 in laryngeal squamous cell carcinoma.J. Otolaryngol. Head Neck Surg.39, 28–34 (2010).
  • Warnecke-Eberz U , BollschweilerE, DrebberUet al.: Prognostic impact of protein overexpression of the proto-oncogene PIM-1 in gastric cancer.AntiCancer Res.29, 4451–4455 (2009).
  • Sepulveda AR , TaoH, CarloniE, SepulvedaJ, GrahamDY, PetersonLE: Screening of gene expression profiles in gastric epithelial cells induced by Helicobacter pylori using microarray analysis.Aliment. Pharmacol. Ther.16(Suppl. 2), 145–157 (2002).
  • Chang YT , WuMS, ChangYJet al.: Distinct gene expression profiles in gastric epithelial cells induced by different clinical isolates of Helicobacter pylori – implication of bacteria and host interaction in gastric carcinogenesis.Hepatogastroenterology53, 484–490 (2006).
  • Hoefnagel JJ , DijkmanR, BassoKet al.: Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling.Blood105, 3671–3678 (2005).
  • His ED , JungSH, LaiRet al.: Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study.Leuk. Lymphoma49, 2081–2090 (2008).
  • Smith RA , CokkinidesV, BrooksD, SaslowD, BrawleyOW: Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening.CA Cancer J. Clin.60, 99–119 (2010).
  • Babel I , BarderasR, Diaz-UriarteR, Martinez-TorrecuadradaJL, Sanchez‑CarbayoM, CasalJI: Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays.Mol. Cell Proteomics.8, 2382–2395 (2009).
  • Jacobs MD , BlackJ, FuterOet al.: Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002.J. Biol. Chem.280, 13728–13734 (2005).
  • Kumar A , MandiyanV, SuzukiYet al.: Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma.J. Mol. Biol.348, 183–193 (2005).
  • Bullock AN , DebreczeniJE, FedorovOY, NelsonA, MarsdenBD, KnappS: Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase.J. Med. Chem.48, 7604–7614 (2005).
  • Debreczeni JE , BullockAN, AtillaGEet al.: Ruthenium half-sandwich complexes bound to protein kinase Pim-1.Angew. Chem. Int. Ed. Engl.45, 1580–1585 (2006).
  • Bregman H , MeggersE: Ruthenium half-sandwich complexes as protein kinase inhibitors: an N-succinimidyl ester for rapid derivatizations of the cyclopentadienyl moiety.Org. Lett.8, 5465–5468 (2006).
  • Pogacic V , BullockAN, FedorovOet al.: Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity.Cancer Res.67, 6916–6924 (2007).
  • Cheney IW , YanS, ApplebyTet al.: Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase.Bioorg. Med. Chem. Lett.17, 1679–1683 (2007).
  • Holder S , LillyM, BrownML: Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.Bioorg. Med. Chem.15, 6463–6473 (2007).
  • Holder S , ZemskovaM, ZhangCet al.: Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase.Mol. Cancer Ther.6, 163–172 (2007).
  • Pierce AC , JacobsM, Stuver-MoodyC: Docking study yields four novel inhibitors of the protooncogene Pim-1 kinase.J. Med. Chem.51, 1972–1975 (2008).
  • Tong Y , StewartKD, ThomasSet al.: Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: chemistry, biological activities, and molecular modeling.Bioorg. Med. Chem. Lett.18, 5206–5208 (2008).
  • Xia Z , KnaakC, MaJet al.: Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.J. Med. Chem.52, 74–86 (2009).
  • Qian K , WangL, CywinCLet al.: Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode.J. Med. Chem.52, 1814–1827 (2009).
  • Tao ZF , HasvoldLA, LeversonJDet al.: Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases.J. Med. Chem.52, 6621–6636 (2009).
  • Akue-Gedu R , RossignolE, AzzaroSet al.: Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors.J. Med. Chem.52, 6369–6381 (2009).
  • Mumenthaler SM , NgPY, HodgeAet al.: Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes.Mol. Cancer Ther.8, 2882–2893 (2009).
  • Fiskus WC , BucklyKM, RaoRet al.: Synergistic activity of co-treatment with PIM1 kinase inhibitor SGI-1776 and histone deacetylase inhibitor panobinostat or heat shock protein 90 inhibitor AUY922 against human CML and myeloproliferative neoplasm (MPN) cells. Presented at:51st ASH Annual Meeting and Exposition. New Orleans, LA, USA, 5–8 December 2009.
  • Xie Y , XuK, DaiBet al.: The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs.Oncogene25, 70–78 (2006).
  • Xie Y , XuK, LinnDEet al.: The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells.J. Biol. Chem.283, 3349–3356 (2008).
  • Kage K , TsukaharaS, SugiyamaTet al.: Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization.Int. J. Cancer97, 626–630 (2002).
  • Hu XF , LiJ, VandervalkS, WangZ, MagnusonNS, XingPX: PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis.J. Clin. Invest.119, 362–375 (2009).
  • Li J , HuXF, LovelandBE, XingPX: Pim-1 expression and monoclonal antibody targeting in human leukemia cell lines.Exp. Hematol.37, 1284–1294 (2009).
  • Peng C , KnebelA, MorriceNAet al.: Pim kinase substrate identification and specificity.J. Biochem.141, 353–362 (2007).
  • Palaty CK , Clark-LewisI, LeungD, PelechSL: Phosphorylation site substrate specificity determinants for the Pim-1 protooncogene-encoded protein kinase.Biochem. Cell Biol.75, 153–162 (1997).
  • Friedmann M , NissenMS, HooverDS, ReevesR, MagnusonNS: Characterization of the proto-oncogene pim-1: kinase activity and substrate recognition sequence.Arch. Biochem. Biophys.298, 594–601 (1992).
  • Nishikawa K , TokerA, JohannesFJ, SongyangZ, CantleyLC: Determination of the specific substrate sequence motifs of protein kinase C isozymes.J. Biol. Chem.272, 952–960 (1997).
  • Walker KS , DeakM, PatersonA, HudsonK, CohenP, AlessiDR: Activation of protein kinase B β and γ isoforms by insulin in vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison with protein kinase B α.Biochem. J.331(Pt 1), 299–308 (1998).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.